US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
CA2260752A1
(en)
*
|
1996-07-23 |
1998-01-29 |
Tanox Pharma B.V. |
Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
JP3581660B2
(ja)
|
1999-04-30 |
2004-10-27 |
ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー |
潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法
|
EP1642596A3
(en)
*
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US6946129B1
(en)
*
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
DE60042785D1
(de)
*
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
AU6929100A
(en)
*
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
EP1839674A1
(en)
*
|
1999-10-04 |
2007-10-03 |
Novartis Vaccines and Diagnostics, Inc. |
CD40 antagonist for treating psoriasis
|
AU1072701A
(en)
*
|
1999-10-04 |
2001-05-10 |
Chiron Corporation |
Cd40 antagonist for treating psoriasis
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
AU1590201A
(en)
*
|
1999-11-09 |
2001-06-06 |
Chiron Corporation |
Compositions and methods for treating autoimmune diseases and transplant rejections
|
GB0001448D0
(en)
|
2000-01-21 |
2000-03-08 |
Novartis Ag |
Organic compounds
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
WO2002011763A1
(en)
*
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
KR20040023565A
(ko)
*
|
2000-09-18 |
2004-03-18 |
아이덱 파마슈티칼즈 코포레이션 |
B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
|
EP2359849A1
(en)
*
|
2001-04-02 |
2011-08-24 |
Genentech, Inc. |
Combination therapy
|
DK1391464T3
(da)
*
|
2001-04-27 |
2008-01-14 |
Kirin Pharma Kk |
Anti-CD40 monoklonalt antistof
|
AU2002347404A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
JP2005510570A
(ja)
*
|
2001-11-26 |
2005-04-21 |
カイロン コーポレイション |
多発性硬化症処置のためのアンタゴニスト抗cd40モノクローナル抗体療法
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
IL163851A0
(en)
*
|
2002-03-01 |
2005-12-18 |
Immunomedics Inc |
Internalizing anti-cd74 antibodies and methods of use
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
AU2003300842A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Tolerrx, Inc. |
Inducing tolerance in primates
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
EP2248830A1
(en)
*
|
2003-11-04 |
2010-11-10 |
Novartis Vaccines and Diagnostics, Inc. |
Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
|
US7312320B2
(en)
*
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US7674884B2
(en)
*
|
2003-12-10 |
2010-03-09 |
Novimmune S.A. |
Neutralizing antibodies and methods of use thereof
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
EP1756162A1
(en)
|
2004-03-23 |
2007-02-28 |
Biogen Idec MA Inc. |
Receptor coupling agents and therapeutic uses thereof
|
WO2006046935A1
(en)
*
|
2004-10-22 |
2006-05-04 |
Applied Molecular Evolution, Inc |
Methods of optimizing antibody variable region binding affinity
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
NZ561655A
(en)
*
|
2005-04-06 |
2010-01-29 |
Bristol Myers Squibb Co |
Methods for treating immune disorders associated with graft transplantation with soluable CTLA4 mutant molecules
|
AU2006247134B2
(en)
|
2005-05-18 |
2012-05-10 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
BRPI0610470A2
(pt)
|
2005-05-26 |
2010-06-22 |
Seattle Genetics Inc |
anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
|
US7668387B2
(en)
*
|
2005-06-20 |
2010-02-23 |
Intel Corporation |
Selective local transient improvement and peaking for video sharpness enhancement
|
EP1912675B1
(en)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
US20070202549A1
(en)
*
|
2005-09-14 |
2007-08-30 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
|
WO2007033369A2
(en)
*
|
2005-09-14 |
2007-03-22 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
|
US20080131914A1
(en)
*
|
2005-09-14 |
2008-06-05 |
Ahearn Joseph M |
Assessing risk of cerebrovascular thrombosis by measuring c4d
|
RU2442605C2
(ru)
|
2005-11-01 |
2012-02-20 |
Новартис Аг |
Применения антител против cd40
|
KR101317235B1
(ko)
|
2006-04-21 |
2013-10-15 |
조마 테크놀로지 리미티드 |
길항제 항-cd40 항체 제약 조성물
|
WO2007130493A2
(en)
*
|
2006-05-03 |
2007-11-15 |
Regents Of The University Of Colorado |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
JP5118139B2
(ja)
*
|
2006-08-04 |
2013-01-16 |
バクスター・インターナショナル・インコーポレイテッド |
新規発症自己免疫性糖尿病を予防および/または逆転させるためのマイクロスフィアに基づく組成物
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
EP2474557B1
(en)
|
2007-07-16 |
2014-08-20 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
RU2553566C2
(ru)
|
2008-01-31 |
2015-06-20 |
Дженентек, Инк. |
АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2406290B1
(en)
|
2009-03-10 |
2017-07-05 |
Baylor Research Institute |
Antigen presenting cell targeted cancer vaccines
|
CN105837691B
(zh)
*
|
2009-03-10 |
2021-06-29 |
贝勒研究院 |
靶向抗原呈递细胞的癌症疫苗
|
WO2011085354A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
LT3178851T
(lt)
|
2010-03-31 |
2020-08-10 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antikūnai
|
PL3789038T3
(pl)
*
|
2010-05-14 |
2023-01-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
EP2683406B1
(en)
|
2011-03-11 |
2019-05-08 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
US9475879B2
(en)
|
2011-04-21 |
2016-10-25 |
Bristol-Myers Squibb Company |
Antibody polypeptides that antagonize CD40
|
CN106928362B
(zh)
|
2011-04-29 |
2021-10-26 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
EA030852B1
(ru)
|
2011-10-13 |
2018-10-31 |
Бристол-Майерс Сквибб Компани |
Полипептиды антител, которые вызывают антагонизм cd40l
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
EP2914627B1
(en)
|
2012-10-30 |
2021-04-07 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
HUE057977T2
(hu)
|
2012-12-13 |
2022-06-28 |
Immunomedics Inc |
Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
CN106573981A
(zh)
|
2014-08-12 |
2017-04-19 |
鳄鱼生物科学公司 |
利用抗cd40抗体的组合疗法
|
RU2762315C2
(ru)
*
|
2014-09-16 |
2021-12-17 |
Юнайтед Байофарма, Инк. |
Лечение и функциональное излечение вич-инфекции моноклональными антителами к cd4, опосредующими конкурентное ингибирование входа вич
|
WO2016049214A1
(en)
|
2014-09-23 |
2016-03-31 |
Genentech, Inc. |
METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
|
EA036498B1
(ru)
|
2014-10-29 |
2020-11-17 |
Сиэтл Дженетикс, Инк. |
Дозировка и введение нефукозилированных анти-cd40 антител
|
EP3229586A4
(en)
|
2014-12-10 |
2018-10-24 |
Regents of the University of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
SI3303395T1
(sl)
*
|
2015-05-29 |
2020-03-31 |
Abbvie Inc. |
Protitelesa proti CD40 in njihove uporabe
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
SI3307322T1
(sl)
|
2015-09-04 |
2021-08-31 |
Primatope Therapeutics Inc. |
Humanizirana protitelesa proti CD40 in njihove uporabe
|
AU2016331819B2
(en)
|
2015-09-30 |
2023-08-24 |
Janssen Biotech, Inc. |
Agonistic antibodies specifically binding human CD40 and methods of use
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
CA3016917A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
CN110392570A
(zh)
|
2017-03-27 |
2019-10-29 |
免疫医疗公司 |
用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
SG11202100510PA
(en)
*
|
2018-07-20 |
2021-02-25 |
Eucure Beijing Biopharma Co Ltd |
Anti-cd40 antibodies and uses thereof
|
US20200190163A1
(en)
*
|
2018-10-26 |
2020-06-18 |
Lijun Wu |
Humanized bcma-car-t cells
|
EP3904386A4
(en)
*
|
2018-12-28 |
2022-09-07 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
ANTIBODIES AND USE THEREOF
|
CN111454364B
(zh)
*
|
2019-03-04 |
2021-03-02 |
北京天广实生物技术股份有限公司 |
结合cd40的抗体及其用途
|
CN117683133A
(zh)
*
|
2019-09-03 |
2024-03-12 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
CN111763259B
(zh)
*
|
2020-09-03 |
2020-12-15 |
北京百奥赛图基因生物技术有限公司 |
抗cd40抗体及其用途
|
JP2024531480A
(ja)
|
2021-08-26 |
2024-08-29 |
デュアリティ バイオロジクス(スーチョウ)カンパニー,リミティド |
ステロイド化合物及びそのコンジュゲート
|
US20230203176A1
(en)
*
|
2021-09-17 |
2023-06-29 |
Novartis Ag |
Methods For Prevention Of Graft Rejection In Xenotransplantation
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|